Bedfordshire and Luton Joint Formulary Formulary

Bedfordshire and Luton Joint Formulary

Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB

Searching for : Fingolimod

Open monograph to display formulary status.

Formulary items found

Status	Description	Section
RED	Fingolimod 500microgram (Capsules)	Malignant disease and immunosuppression, Other immunomodulating drugs, 08.02.04

Links found

MHRA Drug Safety Update (April 2016) - Fingolimod (Gilenya▼): risks of progressive multifocal leukoencephalopathy, basal-cell carcinoma, and opportunistic infections
MHRA Drug Safety Update (Dec 2017): Fingolimod (Gilenya▼): new contraindications in relation to cardiac risk
MHRA Drug Safety Update (Dec 2017): Fingolimod (Gilenya▼): updated advice about risk of cancers and serious infections
MHRA Drug Safety Update (January 2013) - Fingolimod (Gilenya▼): bradycardia and heart block
MHRA Drug Safety Update (January 2021): Fingolimod (Gilenya▼): updated advice about the risks of serious liver injury and herpes meningoencephalitis
MHRA Drug Safety Update (Sept 2019): Fingolimod (Gilenya¥): increased risk of congenital malformations; new contraindication during pregnancy and in women of childbearing potential not using effective contraception
NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis